Last week, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) had released a report stating that "there have been some suspected reports of new-onset or aggravation of pre-existing myasthenia gravis or ocular myasthenia associated with statin use." Myasthenia gravis is an autoimmune neuromuscular disorder that is characterised by fluctuating weakness of the voluntary muscles that control eye movements, facial expression, speaking, swallowing, limb movement and breathing. The common symptoms of myasthenic gravis include drooping eyelids, double vision, problems with chewing or swallowing, speech disturbance, limb weakness and shortness of breath.
The UK MHRA has advised patients with pre-existing myasthenia gravis to be alert to aggravation of symptoms while taking a statin.